EGFR and hepatocellular carcinoma: The results confirm that cells harboring HCC-derived EGFR mutants are erlotinib-resistant, as treatment up to high concentration of erlotinib could only induce partial inhibition of EGFR phosphorylation, and partial or no inhibition of AKT and ERK phosphorylation.